Increases in Health Assessment Questionnaire Disability Index (HAQ-DI) per increase in total Sharp scores (TSS) and intermediate results
Trial | Treatment | HAQ change | SDAI change | fACT (HAQ/SDAI) | SDAI at end point | ACT-HAQ | HAQ at end point | DAM-HAQ | Total Sharp Score at end point | HAQ/TSS |
Established RA | ||||||||||
BELIRA | Glucocorticoids | 0.23 | 11.3 | 0.0207 | 14.4 | 0.30 | 0.93 | 0.63 | 38.1 | 0.0165 |
ATTRACT | Infliximab+MTX | 0.55 | 28.9 | 0.019 | 17.7 | 0.34 | 1.09 | 0.75 | 67.3 | 0.011 |
Placebo | 0.3 | 14.7 | 0.020 | 29.7 | 0.61 | 1.33 | 0.72 | 74.4 | 0.010 | |
DE019 | Adalimumab+MTX | 0.53 | 22.1 | 0.024 | 18.6 | 0.45 | 0.92 | 0.47 | 67.5 | 0.007 |
LEF | Leflunomide | 0.58 | 27.8 | 0.021 | 21.9 | 0.46 | 0.93 | 0.47 | 30.2 | 0.016 |
MTX | 0.62 | 30.3 | 0.020 | 20.4 | 0.42 | 0.88 | 0.46 | 26 | 0.018 | |
Salazopyrine | 0.54 | 31.9 | 0.017 | 15.9 | 0.27 | 0.78 | 0.51 | 47 | 0.011 | |
TEMPO | Etanercept+MTX | 0.68 | 23.1 | 0.029 | 11.1 | 0.33 | 0.69 | 0.36 | 32.4 | 0.011 |
Etanercept | 0.55 | 22.3 | 0.025 | 13.8 | 0.34 | 0.83 | 0.49 | 26.5 | 0.018 | |
MTX | 0.6 | 26 | 0.023 | 15.6 | 0.36 | 0.9 | 0.54 | 35.3 | 0.015 | |
Mean | – | – | – | 0.022±0.004 | – | – | – | 0.53±0.13 | – | 0.013±0.004 |
Early RA | ||||||||||
ASPIRE | Infliximab+MTX | 0.89 | 26.4 | 0.034 | 11.6 | 0.39 | 0.61 | 0.22 | 11.5 | 0.019 |
MTX | 0.73 | 22.5 | 0.032 | 15.5 | 0.50 | 0.81 | 0.31 | 15.4 | 0.020 | |
ERA | Etanercept | 0.76 | 27.1 | 0.028 | 17.6 | 0.49 | 0.7 | 0.21 | 11.6 | 0.018 |
MTX | 0.75 | 25.4 | 0.030 | 18.4 | 0.54 | 0.68 | 0.14 | 13.3 | 0.010 | |
PREMIER | Adalimumab | 0.9 | 34.5 | 0.026 | 13.7 | 0.36 | 0.69 | 0.33 | 21.3 | 0.016 |
MTX | 0.88 | 35.7 | 0.025 | 13.7 | 0.34 | 0.62 | 0.28 | 27.4 | 0.010 | |
Adalimumab+MTX | 1.06 | 39.7 | 0.027 | 8.7 | 0.23 | 0.41 | 0.18 | 20 | 0.009 | |
Mean | – | – | – | 0.029+0.003 | – | – | – | 0.24±0.07 | – | 0.015±0.005 |
ACT-HAQ, activity-related HAQ component; ASPIRE, ‘Active-controlled Study of Patents receiving Infliximab for the treatment of RA of Early onset’; ATTRACT, ‘Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy’; BELIRA, ‘BEst LIfe with Rheumatoid Arthritis’; DAM-HAQ, damage-related HAQ component; ERA, ‘Early Rheumatoid Arthritis’; fACT, change in HAQ seen per change in SDAI; LEF, leflunomide; MTX, methotrexate; SDAI, Simplified Disease Activity Index; TEMPO, ‘Trial of Etanercept and Methotrexate with radiographic Patient Outcomes’; TSS, total Sharp score.